Dysregulation of anergy-related factors involved in regulatory T cells defects in Systemic Lupus Erythematosus patients: Rapamycin and Vitamin D efficacy in restoring regulatory T cells

International Journal of Rheumatic Diseases

Volumn 19, Issue 12, 2016, Pages 1294-1303

  Banica, Leontina M ^a,d   Besliu, Alina N ^a   Pistol, Gina C ^a   Stavaru, Crina ^a   Vlad, Violeta ^b   Predeteanu, Denisa ^b,c   Ionescu, Ruxandra ^b,c   Stefanescu, Maria ^a   Matache, Cristiana ^a  

^a CANTACUZINO INSTITUTE   (Romania)

^b Sf Maria Clinical Hospital   (Romania)

^c CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^d UNIVERSITY OF BUCHAREST   (Romania)

Author keywords

anergy related factors; rapamycin; regulatory T cells; systemic lupus erythematosus; vitamin D

Indexed keywords

CASITAS B CELL LYMPHOMA B PROTEIN; CD28 ANTIBODY; CD3 ANTIBODY; GENE RELATED TO ANERGY IN LYMPHOCYTE PROTEIN; MEMBRANE PROTEIN; MESSENGER RNA; MONOCLONAL ANTIBODY; RAPAMYCIN; RECOMBINANT INTERLEUKIN 2; UNCLASSIFIED DRUG; VITAMIN D; CALCITRIOL; CBL PROTEIN; CBLB PROTEIN, HUMAN; EARLY GROWTH RESPONSE FACTOR 2; EARLY GROWTH RESPONSE FACTOR 3; EGR2 PROTEIN, HUMAN; EGR3 PROTEIN, HUMAN; IMMUNOLOGIC FACTOR; RNF128 PROTEIN, HUMAN; SIGNAL TRANSDUCING ADAPTOR PROTEIN; UBIQUITIN PROTEIN LIGASE;

ARTICLE; CD4+ T LYMPHOCYTE; CELL ACTIVITY; CELL EXPANSION; CONTROLLED STUDY; EGR2 GENE; EGR3 GENE; GENE; HUMAN; HUMAN CELL; IN VITRO STUDY; LYMPHOCYTE COUNT; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE PROLIFERATION; LYMPHOCYTE SUBPOPULATION; MAJOR CLINICAL STUDY; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SYSTEMIC LUPUS ERYTHEMATOSUS; BLOOD; CASE CONTROL STUDY; CELL CULTURE; CELL PROLIFERATION; CLONAL ANERGY; DRUG EFFECTS; GENETICS; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHOCYTE ACTIVATION; METABOLISM; TIME FACTOR;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; CALCITRIOL; CASE-CONTROL STUDIES; CELL PROLIFERATION; CELLS, CULTURED; CLONAL ANERGY; EARLY GROWTH RESPONSE PROTEIN 2; EARLY GROWTH RESPONSE PROTEIN 3; HUMANS; IMMUNOLOGIC FACTORS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHOCYTE ACTIVATION; PHENOTYPE; PROTO-ONCOGENE PROTEINS C-CBL; RNA, MESSENGER; SELF TOLERANCE; SIROLIMUS; T-LYMPHOCYTES, REGULATORY; TIME FACTORS; UBIQUITIN-PROTEIN LIGASES;

EID: 84933575724     PISSN: 17561841     EISSN: 1756185X     Source Type: Journal    
DOI: 10.1111/1756-185X.12509     Document Type: Article

References (38)

1. Crispín JC, Kyttaris VC, Terhorst C, Tsokos GC (2010) T cells as therapeutic targets in SLE. Nat Rev Rheumatol 6, 317–25.
2. Mueller DL (2010) Mechanisms maintaining peripheral tolerance. Nat Immunol 11, 21–7.
3. Bonelli M, Savitskaya A, von Dalwigk K et al. (2008) Quantitative and qualitative deficiencies of regulatory T cells in patients with systemic lupus erythematosus (SLE). Int Immunol 20, 861–8.
4. Banica L, Besliu A, Pistol G et al. (2000) Quantification and molecular characterization of regulatory T cells in connective tissue diseases. Autoimmunity 42, 41–9.
5. Yi Y, McNerney M, Datta SK (2000) Regulatory defects in Cbl and mitogen-activated protein kinase (extracellular signal-related kinase) pathways cause persistent hyperexpression of CD40 ligand in human lupus T cells. J Immunol 165, 6627–34.
6. Safford M, Collins S, Lutz MA et al. (2005) Egr-2 and Egr-3 are negative regulators of T cell activation. Nat Immunol 6, 472–80.
7. Zheng Y, Zha Y, Gajewski TF (2008) Molecular regulation of T-cell anergy. EMBO Rep 9, 50–5.
8. Mozes E, Sela U, Sharabi A (2008) A novel synthetic peptide for the specific treatment of lupus: clinical effects and mechanism of action. Isr Med Assoc J 10, 40–2.
9. Myouzen K, Kochi Y, Shimane K et al. (2010) Regulatory polymorphisms in EGR2 are associated with susceptibility to systemic lupus erythematosus. Hum Mol Genet 19, 2313–20.
10. Bachmaier K, Krawczyk C, Kozieradzki I et al. (2000) Negative regulation of lymphocyte activation and autoimmunity by the molecular adaptor Cbl-b. Nature 403, 211–6.
11. Chiang YJ, Kole HK, Brown K et al. (2000) Cbl-b regulates the CD28 dependence of T-cell activation. Nature 403, 216–20.
12. Wohlfert EA, Gorelik L, Mittler R, Flavell RA, Clark RB (2006) Cutting edge: deficiency in the E3 ubiquitin ligase Cbl-b results in a multifunctional defect in T cell TGF-beta sensitivity in vitro and in vivo. J Immunol 176, 1316–20.
13. Adams CO, Housley WJ, Bhowmick S et al. (2010) Cbl-b(-/-) T cells demonstrate in vivo resistance to regulatory T cells but a context-dependent resistance to TGF-beta. J Immunol 185, 2051–8.
14. Anandasabapathy N, Ford GS, Bloom D et al. (2003) GRAIL: an E3 ubiquitin ligase that inhibits cytokine gene transcription is expressed in anergic CD4 + T cells. Immunity 18, 535–47.
15. Seroogy CM, Soares L, Ranheim EA et al. (2004) The gene related to anergy in lymphocytes, an E3 ubiquitin ligase, is necessary for anergy induction in CD4 T cells. J Immunol 173, 79–85.
16. MacKenzie DA, Schartner J, Lin J et al. (2007) GRAIL is up-regulated in CD4 + CD25 + T regulatory cells and is sufficient for conversion of T cells to a regulatory phenotype. J Biol Chem 282, 9696–702.
17. Nurieva RI, Zheng S, Jin W et al. (2010) The E3 ubiquitin ligase GRAIL regulates T cell tolerance and regulatory T cell function by mediating T cell receptor-CD3 degradation. Immunity 32, 670–80.
18. Brusko TM, Putnam AL, Bluestone JA (2008) Human regulatory T cells: role in autoimmune disease and therapeutic opportunities. Immunol Rev 223, 371–90.
19. Maiese K (2013) Therapeutic targets for cancer: current concepts with PI 3-K, Akt, & mTOR. Indian J Med Res 137, 243–6.
20. Kang SW, Kim SH, Lee N et al. (2012) 1,25-Dihyroxyvitamin D3 promotes FOXP3 expression via binding to vitamin D response elements in its conserved noncoding sequence region. J Immunol 188, 5276–82.
21. Battaglia M, Stabilini A, Roncarolo MG (2005) Rapamycin selectively expands CD4 + CD25 + FoxP3 + regulatory T cells. Blood 105, 4743–8.
22. Ghoreishi M, Bach P, Obst J, Komba M, Fleet JC, Dutz JP (2009) Expansion of antigen-specific regulatory T cells with the topical vitamin d analog calcipotriol. J Immunol 182, 6071–8.
23. Tan EM, Cohen AS, Fries JF et al. (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25, 1271–7.
24. Rozen S, Skaletsky H (2000) Primer3 on the WWW for general users and for biologist programmers. Methods Mol Biol 132, 365–86.
25. Zhang J, Bárdos T, Li D et al. (2002) Cutting edge: regulation of T cell activation threshold by CD28 costimulation through targeting Cbl-b for ubiquitination. J Immunol 169, 2236–40.
26. Matache C, Onu A, Stefanescu M et al. (2001) Dysregulation of p56lck kinase in patients with systemic lupus erythematosus. Autoimmunity 34, 27–38.
27. Zheng Y, Collins SL, Lutz MA et al. (2007) A role for mammalian target of rapamycin in regulating T cell activation versus anergy. J Immunol 178, 2163–70.
28. Vargas-Rojas MI, Crispín JC, Richaud-Patin Y, Alcocer-Varela J (2008) Quantitative and qualitative normal regulatory T cells are not capable of inducing suppression in SLE patients due to T-cell resistance. Lupus 17, 289–94.
29. Loeser S, Penninger JM (2007) Regulation of peripheral T cell tolerance by the E3 ubiquitin ligase Cbl-b. Semin Immunol 19, 206–14.
30. Doníz-Padilla L, Martínez-Jiménez V, Niño-Moreno P et al. (2011) Expression and function of Cbl-b in T cells from patients with systemic lupus erythematosus, and detection of the 2126 A/G Cblb gene polymorphism in the Mexican mestizo population. Lupus 20, 628–35.
31. Li D, Gál I, Vermes C et al. (2004) Cutting edge: Cbl-b: one of the key molecules tuning CD28- and CTLA-4-mediated T cell costimulation. J Immunol 173, 7135–9.
32. Chang X, Chen L, Wen J et al. (2006) Foxp3 controls autoreactive T cell activation through transcriptional regulation of early growth response genes and E3 ubiquitin ligase genes, independently of thymic selection. Clin Immunol 121, 274–85.
33. Sela U, Dayan M, Hershkoviz R, Lider O, Mozes E (2008) A peptide that ameliorates lupus up-regulates the diminished expression of early growth response factors 2 and 3. J Immunol 180, 1584–91.
34. Sharabi A, Mozes E (2008) The suppression of murine lupus by a tolerogenic peptide involves foxp3-expressing CD8 cells that are required for the optimal induction and function of foxp3-expressing CD4 cells. J Immunol 181, 3243–51.
35. Terrier B, Derian N, Schoindre Y et al. (2012) Restoration of regulatory and effector T cell balance and B cell homeostasis in systemic lupus erythematosus patients through vitamin D supplementation. Arthritis Res Ther 14, R221.
36. Ishida H, Kumagai S, Umehara H et al. (1987) Impaired expression of high affinity interleukin 2 receptors on activated lymphocytes from patients with systemic lupus Erythematosus. J Immunol 139, 1070–4.
37. Lieberman LA, Tsokos GC (2010) The IL-2 defect in Systemic Lupus Erythematosus disease has an expansive effect on host Immunity. J Biomed Biotechnol 2010:740619. doi: 10.1155/2010/740619.
38. Czifra G, Tóth B, Kovács I et al. (2014) The in vitro treatment with vitamin D3 is ineffective on the expression of PKC isoenzymes, but decreases further the impaired production of IL-2 in the T lymphocytes of SLE patients. Rheumatol Int 34, 717–20.